ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Soleno Therapeutics, Inc. ?
1
With a growth in Net Sales of INF%, the company declared Outstanding results in Sep 25
- The company has declared positive results in Jan 70 after 7 consecutive negative quarters
- ROCE(HY) Highest at -20.66%
- OPERATING PROFIT(Q) Highest at USD 23.22 MM
- PRE-TAX PROFIT(Q) Highest at USD 26.63 MM
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Soleno Therapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Soleno Therapeutics, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Soleno Therapeutics, Inc.
-37.5%
-0.44
74.56%
S&P 500
16.12%
0.84
19.28%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
151.03%
EBIT Growth (5y)
-193.58%
EBIT to Interest (avg)
-54.29
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.03
Sales to Capital Employed (avg)
0.15
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.48
EV to EBIT
-15.13
EV to EBITDA
-15.50
EV to Capital Employed
27.47
EV to Sales
12.92
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-181.53%
ROE (Latest)
-14.84%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend30What is working for the Company
ROCE(HY)
Highest at -20.66%
OPERATING PROFIT(Q)
Highest at USD 23.22 MM
PRE-TAX PROFIT(Q)
Highest at USD 26.63 MM
NET PROFIT(Q)
Highest at USD 26.63 MM
RAW MATERIAL COST(Y)
Fallen by -9,827% (YoY
NET SALES(9M)
Higher at USD 98.67 MM
CASH AND EQV(HY)
Highest at USD 785.78 MM
INVENTORY TURNOVER RATIO(HY)
Highest at 0.85 times
DEBTORS TURNOVER RATIO(HY)
Highest at 7.74 times
EPS(Q)
Highest at USD 0.47
-5What is not working for the Company
INTEREST(9M)
At USD 4.13 MM has Grown at inf%
DEBT-EQUITY RATIO
(HY)
Highest at -90.19 %
Here's what is working for Soleno Therapeutics, Inc.
Net Sales
At USD 98.67 MM has Grown at inf%
Year on Year (YoY)MOJO Watch
Sales trend is very positive
Net Sales (USD MM)
Operating Profit
Highest at USD 23.22 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Operating Profit trend is quite positive
Operating Profit (USD MM)
Pre-Tax Profit
Highest at USD 26.63 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Pre-Tax Profit
At USD 26.63 MM has Grown at 135.16%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD 26.63 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Net Profit
At USD 26.63 MM has Grown at 135.16%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
EPS
Highest at USD 0.47
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Cash and Eqv
Highest at USD 785.78 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Inventory Turnover Ratio
Highest at 0.85 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Debtors Turnover Ratio
Highest at 7.74 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Net Sales
Higher at USD 98.67 MM
than preceding 12 month period ended Sep 2025MOJO Watch
In the nine month period the company has already crossed sales of the previous twelve months
Net Sales (USD MM)
Raw Material Cost
Fallen by -9,827% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Soleno Therapeutics, Inc.
Interest
At USD 4.13 MM has Grown at inf%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
Debt-Equity Ratio
Highest at -90.19 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Non Operating Income
Highest at USD 0.2 MM
in the last five periodsMOJO Watch
Increased income from non business activities may not be sustainable
Non Operating income
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
